Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CDK7 inhibitor, Q901 synergizes with topoisomerase 1 inhibition by disrupting MYC/E2F-driven transcription program

ABSTRACT: Cyclin-dependent kinase 7 (CDK7) functions as both a cell cycle regulator through activation of CDKs 1, 2, 4, and 6, and as a critical component of transcription factor II H (TFIIH) mediating RNA Polymerase II transcription. This study investigates the transcriptional impact of Q901, a highly selective CDK7 inhibitor in clinical development. Our findings demonstrate that Q901 primarily disrupts oncogenic transcription programs driven by MYC and E2F, evidenced by dramatic stabilization of CDK7 binding and reduced occupancy of MYC, E2F, and RNA Pol II at promoter-proximal regions. This leads to downregulation of genes involved in DNA damage repair and cell cycle control pathways. Further investigation revealed a novel therapeutic mechanism to overcome topoisomerase I (TOP1) inhibitor resistance. While cancer cells typically evade TOP1 inhibitors when elongating RNA Pol II encounters TOP1-DNA protein crosslinks (TOP1-DPCs), triggering repair mechanisms, Q901 prevents RNA Pol II transition from initiation to elongation as well as DNA repair pathway, thereby stabilizing TOP1-DPCs. In vivo studies demonstrated synergistic tumor growth inhibition when combining Q901 with TOP1 inhibitor-based antibody-drug conjugates (TOP1i-ADCs), including trastuzumab deruxtecan and sacituzumab govitecan. These results collectively demonstrate that a combination of Q901 and TOP1i-ADC could be a promising therapeutic approach for cancers with limited response to TOP1i-ADC therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE292860 | GEO | 2026/02/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Selective CDK7 Inhibition Sensitizes Tumors to Topoisomerase I Inhibitor-Antibody Drug Conjugates by Blocking The Transition of The RNA polymerase II Initiation Complex into Elongation [ChIP-seq]

Project description:This study investigates the transcriptional impact of Q901, a highly selective CDK7 inhibitor in clinical development. Q901 primarily disrupted MYC and E2F-dependent transcription program, downregulating cell cycle control and DNA damage repair pathways. CDK7 binding at the promoter-proximal regions was dramatically stabilized by Q901, leading to reduced occupancy of MYC, E2F, and RNA Polymerase II (RNAPII). These findings offered a novel therapeutic strategy to enhance cancer susceptibility to TOP1-DNA protein crosslinks (TOP1-DPCs) induced by TOP1 inhibitors. Resistance to TOP1 inhibitors arises through activation of DNA repair pathway when elongating RNAPII encounters TOP1-DPCs. By suppressing RNAPII transition from initiation to elongation and DNA repair pathways, Q901 stabilizes TOP1-DPCs and sensitizes tumor to TOP1 inhibitors. Preclinical studies demonstrated enhanced tumor suppression when combining Q901 with TOP1 inhibitor-based antibody-drug conjugates (TOP1i-ADCs), highlighting its potential as a therapeutic option for cancers resistant to TOP1i-ADC therapy.

2026-02-12 | GSE292907 | GEO

Selective CDK7 Inhibition Sensitizes Tumors to Topoisomerase I Inhibitor-Antibody Drug Conjugates by Blocking The Transition of The RNA polymerase II Initiation Complex into Elongation [fastGRO]

2026-02-12 | GSE292846 | GEO

CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release

Project description:Cyclin-dependent kinase 7 (CDK7), part of the general transcription factor TFIIH, promotes gene transcription by phosphorylating the C-terminal domain of RNA polymerase II (RNA Pol II). Here, we combine rapid CDK7 kinase inhibition with multi-omics analysis to unravel the direct functions of CDK7 in human cells. CDK7 inhibition causes RNA Pol II retention at promoters, leading to decreased RNA Pol II initiation and immediate global downregulation of transcript synthesis. Elongation, termination, and recruitment of co-transcriptional factors are not directly affected. Although RNA Pol II, initiation factors, and Mediator accumulate at promoters, RNA Pol II complexes can also proceed into gene bodies without promoter-proximal pausing while retaining initiation factors and Mediator. Further downstream, RNA Pol II phosphorylation increases and initiation factors and Mediator are released, allowing recruitment of elongation factors and an increase in RNA Pol II elongation velocity. Collectively, CDK7 kinase activity promotes the release of initiation factors and Mediator from RNA Pol II, facilitating RNA Pol II escape from the promoter.

2024-05-31 | PXD037842 | Pride

Transcription-coupled DNA-Protein Crosslink repair by CSB and CRL4(CSA)-mediated degradation

Project description:DNA-protein crosslinks (DPCs), arise from enzymatic intermediates, endogenous metabolism or exogenous chemicals like chemotherapeutics. DPCs are highly cytotoxic as they will impede DNA transacting processes such as replication, which is counteracted by proteolysis-mediated DPC removal by the protease SPRTN or the proteasome. However, how DPCs affect transcription and how transcription-blocking DPCs are repaired remains largely unknown. Here, we show that DPCs severely inhibit RNA polymerase II (Pol II)-mediated transcription, resulting in the recruitment of the transcription-coupled nucleotide excision repair (TC-NER) factors CSA and CSB. Interestingly, CSA and CSB are indispensable for transcription-coupled DPC (TC-DPC) repair, while the downstream TC-NER factors UVSSA and XPA are not, indicative of a non-canonical TC-NER mechanism. TC-DPC repair functions independent of SPRTN, but is mediated by the activities of the ubiquitin ligase CRL4CSA and the proteasome. Thus, DPCs are preferentially repaired in genes by a dedicated transcription-coupled repair mechanism, which is crucial to warrant correct transcription.

2024-02-09 | PXD041679 | Pride

CDK7 inhibition suppresses Hippo-YAP signaling to reverse CDK4/6 inhibitor resistance in hormone receptor-positive breast cancer [ChIP-seq]

Project description:Hormone receptor-positive (HR+) breast cancer is the most prevalent breast cancer subtype, and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the mainstay of treatment for metastatic disease. Amplification or overexpression of CDK6 is an established driver of CDK4/6i resistance, for which no targeted strategy exists. Through a kinase-inhibitor screen for compounds that suppress CDK6, we identified PIK-75 as an agent that downregulates CDK6 and reverses CDK4/6i resistance in HR+ breast cancer. We found that PIK-75 acts as an inhibitor of CDK7, abolishing phosphorylation of serine 5 on the RNA polymerase II (Pol II) carboxy-terminal domain. The structurally distinct CDK7 inhibitor THZ1 and shRNA-mediated CDK7 depletion both phenocopied the suppression of yes-associated protein (YAP) and CDK6, establishing the effect as CDK7-dependent. Chromatin immunoprecipitation demonstrated that CDK7 inhibition reduced Pol II-serine 5 occupancy at the YAP1 promoter, downregulating YAP1 transcription and YAP-TEAD output. Genome-wide, PIK-75 induced promoter-proximal Pol II pausing that was more pronounced at oncogenic-pathway genes, and transcriptomic and proteomic profiling confirmed a bona fide CDK7-inhibition signature, accompanied by widespread intron retention, rather than a phosphoinositide 3-kinase-dominated response. In CDK6-overexpressing xenografts, PIK-75 combined with abemaciclib reversed resistance and suppressed YAP and CDK6 in vivo. These findings define a transcriptional axis linking CDK7 and Pol II-serine 5 phosphorylation to Hippo-YAP signaling and CDK6, and establish CDK7 inhibition as a rational strategy for CDK4/6i-resistant HR+ breast cancer, supporting evaluation of clinical-stage CDK7 inhibitors in combination with continued CDK4/6 inhibition.

2026-06-20 | GSE335518 | GEO

CDK7 inhibition suppresses Hippo-YAP signaling to reverse CDK4/6 inhibitor resistance in hormone receptor-positive breast cancer

2026-06-20 | GSE335516 | GEO

CDK7 kinase activity promotes RNA polymerase II promoter escape by facilitating initiation factor release

Project description:Cyclin-dependent kinase 7 (CDK7), part of general transcription factor TFIIH, promotes gene transcription by phosphorylating the C-terminal domain of RNA polymerase II (Pol II). Here, we combine rapid CDK7 kinase inhibition with multi-omics analysis to unravel the direct functions of CDK7 in human cells. CDK7 inhibition causes Pol II retention at promoters, leading to decreased Pol II initiation and immediate global downregulation of transcript synthesis. Elongation, termination, and recruitment of co-transcriptional factors are not directly affected. Although Pol II, initiation factors, and Mediator accumulate at promoters, Pol II complexes can also proceed into gene bodies without promoter-proximal pausing while retaining initiation factors and Mediator. Further downstream, Pol II phosphorylation increases, initiation factors and Mediator are released, allowing recruitment of elongation factors and increase in Pol II elongation velocity. Collectively, CDK7 kinase activity promotes the release of initiation factors and Mediator from Pol II, facilitating Pol II escape from the promoter.

2024-06-01 | GSE218269 | GEO

RNA Pol II ChIP-seq analysis after THZ1 treatment in TL-Om1 cells

Project description:ChIP-seq analysis was performed in an adult T-cell leukemia/lymphoma cell line (TL-Om1) to analyze DNA bindings of RNA polymerase II (Pol II) after treatment with the THZ1 CDK7 inhibitor.

2017-10-05 | GSE85693 | GEO

Human TFIIH kinase CDK7 regulates transcription-associated epigenetic modification

Project description:CDK7 phosphorylates the RNA polymerase II (pol II) CTD and activates the P-TEFb- associated kinase, CDK9, but its regulatory roles remain obscure. Using human CDK7 analog-sensitive (CDK7as) cells, we observed reduced capping enzyme recruitment, increased pol II promoter-proximal pausing, and defective termination at gene 3'-ends upon CDK7 inhibition. We also found that CDK7 regulates chromatin modifications downstream of transcription start sites. H3K4me3 spreading was restricted at gene 5'-ends and H3K36me3 was displaced toward gene 3'-ends in CDK7as cells. Together, these results implicate a CDK7-dependent "CTD code" that regulates epigenetic marks in addition to RNA processing and pol II pausing.

2017-08-01 | GSE100040 | GEO

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Project description:Therapeutic targeting of CDK7 has proven beneficial in pre-clinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates with E2F and MYC transcriptional programs in multiple myeloma (MM) patient cells; and its selective targeting counteracts E2F activity via perturbation of the CDKs/Rb axis and impairs MYC-regulated metabolic gene signatures translating into defects in glycolysis and reduced levels of lactate production in MM cells. CDK7 inhibition using the covalent small molecule inhibitor YKL-5-124 elicits a strong therapeutic response with minimal effects on normal cells, and causes in vivo tumor regression increasing survival in several MM mouse models including a genetically engineered mouse model of MYC-dependent MM. Through its role as a critical cofactor and regulator of MYC and E2F activity, CDK7 is therefore a master regulator of oncogenic cellular programs supporting MM growth and survival, and a valuable therapeutic target providing rationale for development of YKL-5-124 for clinical use.

2023-02-01 | GSE172441 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data